User profiles for A. Onn

Amir Onn

SHEBA MEDICAL CENTER
Verified email at sheba.health.gov.il
Cited by 5351

Angiogenesis and lung cancer: prognostic and therapeutic implications

RS Herbst, A Onn, A Sandler - Journal of Clinical Oncology, 2005 - ascopubs.org
Lung cancer is the most common cause of cancer death worldwide, with most patients dying
with metastatic disease. The prognosis for the majority of patients remains poor. It is evident …

Vandetanib (ZD6474): an orally available receptor tyrosine kinase inhibitor that selectively targets pathways critical for tumor growth and angiogenesis

…, JV Heymach, MS O'Reilly, A Onn… - Expert opinion on …, 2007 - Taylor & Francis
Vandetanib (ZD6474; ZACTIMA™, AstraZeneca) is a once-daily, orally available agent with
potential for use in a number of solid tumor types. Vandetanib targets key signaling …

[HTML][HTML] Alternating electric fields (tumor-treating fields therapy) can improve chemotherapy treatment efficacy in non-small cell lung cancer both in vitro and in vivo

…, T Voloshin, R Blatt, S Cahal, A Itzhaki, A Onn… - Seminars in …, 2014 - Elsevier
Non-small cell lung cancer (NSCLC) is one of the leading causes of cancer-related deaths
worldwide. Common treatment modalities for NSCLC include surgery, radiotherapy, …

Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trial

…, J Raynaud, J Mendelsohn, G Batist, A Onn… - Nature medicine, 2019 - nature.com
Precision medicine focuses on DNA abnormalities, but not all tumors have tractable genomic
alterations. The WINTHER trial ( NCT01856296 ) navigated patients to therapy on the basis …

[HTML][HTML] BRAF mutant lung cancer: programmed death ligand 1 expression, tumor mutational burden, microsatellite instability status, and response to immune check …

…, N Peled, H Nechushtan, M Wollner, A Onn… - Journal of Thoracic …, 2018 - Elsevier
Introduction The efficacy of immune checkpoint inhibitors (ICPi) in BRAF mutant NSCLC is
unknown. Methods Multi-institutional retrospective chart review identified 39 patients with …

[HTML][HTML] Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX …

…, L Sharma, H Dadhich, RV Nagarkar, A Onn… - Annals of …, 2016 - Elsevier
Background Afatinib has demonstrated clinical benefit in patients with non-small-cell lung
cancer progressing after treatment with erlotinib/gefitinib. This phase III trial prospectively …

Development of an orthotopic model to study the biology and therapy of primary human lung cancer in nude mice

A Onn, T Isobe, S Itasaka, W Wu, MS O'Reilly… - Clinical cancer …, 2003 - AACR
Purpose: This study was conducted to develop biologically relevant animal models of human
lung cancer that are reproducible, inexpensive, and easy to perform. Experimental Design: …

Weight loss and improvement of obesity-related illness in 500 US patients following laparoscopic adjustable gastric banding procedure

H Spivak, MF Hewitt, A Onn, EE Half - The American journal of surgery, 2005 - Elsevier
BACKGROUND: Obesity and its related illness is a primary health concern today. METHODS:
Five hundred morbidly obese patients (mean age 42 years; mean preoperative weight 123 …

Exposure of melanoma cells to dacarbazine results in enhanced tumor growth and metastasis in vivo

DC Lev, A Onn, VO Melinkova, C Miller… - Journal of Clinical …, 2004 - ascopubs.org
Purpose In recent years, the incidence of cutaneous melanoma has increased more than
that of any other cancer. Dacarbazine is considered the gold standard for treatment, having a …

[HTML][HTML] Exhaled breath analysis for monitoring response to treatment in advanced lung cancer

…, O Liran, N Gai-Mor, M Ilouze, A Onn… - Journal of Thoracic …, 2016 - Elsevier
Introduction The Response Evaluation Criteria in Solid Tumors (RECIST) serve as the
accepted standard to monitor treatment efficacy in lung cancer. However, the time intervals …